Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocyto...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T. Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N. Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa
Μορφή: Άρθρο
Γλώσσα:English
Έκδοση: Wiley 2023-11-01
Σειρά:HemaSphere
Διαθέσιμο Online:http://journals.lww.com/10.1097/HS9.0000000000000963

Διαδίκτυο

http://journals.lww.com/10.1097/HS9.0000000000000963

Παρόμοια τεκμήρια